<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="44490">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02527109</url>
  </required_header>
  <id_info>
    <org_study_id>RDD 110</org_study_id>
    <nct_id>NCT02527109</nct_id>
  </id_info>
  <brief_title>The Effect of Intra-anal Nifedipine, Used As Add-on to Conservative Therapy, on Pain in Patients With Anal Fissure</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>RDD Pharma Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RDD Pharma Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to examine the effect of Nifedipine, applied intra-anally
      through our drug delivery device, on rectal pain severity in anal fissure patients that are
      being managed with conservative treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blinded study. All patients in the study will be treated with
      the conservative standard of care for anal fissure. Study medication will be used as an
      add-on to conservative therapy, and will consist of 3 groups:

        1. Treatment Group 1- 12 mg of Nifedipine to be self-administered twice daily.

        2. Treatment Group 2- 12 mg of Nifedipine to be self-administered once daily in the
           morning hours and placebo to be self-administered in the evening.

        3. Placebo Group - Placebo to be self-administered twice daily. Approximately 330 subjects
           will participate in this study. A screening visit will be used to determine subject
           suitability for inclusion in the trial. Within one week of the screening visit,
           subjects who meet all inclusion criteria and none of the exclusion criteria will
           receive either Nifedipine 12 mg X2 a day (BID) (24 mg/day total) or Nifedipine 12 mg
           X1/day to be administered in the morning hours and a matching placebo X1/day to be
           administered in the evening hours (12 mg/day total) or a matching placebo X2 a day
           (BID) (0 mg/day total) for a period of 8 weeks. During this period, 4 study visits (at
           0, 2, 5, and 8 weeks) will take place. Study medication and placebo will be
           administered BID (in the morning and in the evening). In addition to receiving study
           medication, subjects will be maintained on a conservative standard treatment for Anal
           Fissure: sitz baths, high fiber diet, stool softeners and plenty of fluids.

      Upon completion of the treatment cycle, patients will be contacted by phone (at weeks 10, 13
      and 16) and will be questioned about recurrent symptoms e.g. pain or bleeding.

      Patients that:

        1. Were enrolled to one of the investigational groups ,and completed the 8 weeks treatment
           period or discontinued treatment because the investigator deemed them as healed AND

        2. Experience symptoms of recurrence AND ARE

        3. Willing to participate in an open label extension will receive Nifedipine 12 mg X2 a
           day (BID) for a period of 8 weeks. During this period, 4 study visits (at 0, 2, 5, and
           8 weeks from the start of retreatment) will take place.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rectal pain and measured by VAS</measure>
    <time_frame>measured at day 56</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Healing of anal fissure</measure>
    <time_frame>day 56</time_frame>
    <description>Healing is defined by lack of pain AND evidence of epithelization in a physical examination</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Chronic Anal Fissure</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intra-anal placebo administered BID.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nifedipine 12 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intra-anal Nifedipine 12 mg administered OD.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nifedipine 24 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intra-anal Nifedipine 12 mg administered BID.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nifedipine</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Nifedipine 12 mg/day</arm_group_label>
    <arm_group_label>Nifedipine 24 mg/day</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Subjects meeting the following criteria will be eligible to participate in the trial:

          1. Single anal fissure;

          2. Signed written informed consent;

          3. Male or female subjects 18 to 65 years of age inclusive;

          4. Has chronic anal fissure defined as history of rectal pain at least three days a week
             for at least 6 weeks - or more AND at least one of the following:

               -  Sentinel skin tag

               -  Hypertrophied anal papilla

               -  Exposure of the underlying internal anal sphincter

               -  Anal cicatrisation

          5. Visual analogue scale of average 24 hours rectal pain (VAS) of &gt; 40 mm in screening
             visit

          6. Capable of using the IVRS and able to adequately communicate comprehension of the
             IVRS questions to the investigator

          7. If female, is non-lactating, has a negative urine pregnancy test result, and does not
             plan on becoming pregnant during the study, or not of childbearing potential
             (hysterectomy or tubal ligation at least 6 months prior to entry to the study or
             post-menopausal for 1 year); if of childbearing potential (including peri-menopausal
             women who have had a menstrual period within one year) must practice or be willing to
             continue to practice acceptable birth control from screening and until 1 week after
             the study medication has been discontinued.

        Acceptable birth control includes :

          -  combined (estrogen and progestogen containing) hormonal contraception

          -  associated with inhibition of ovulation; oral OR intravaginal OR transdermal.

          -  progestogen-only hormonal contraception associated with inhibition of ovulation: oral
             OR injectable OR implantable.

          -  progestogen-only oral hormonal contraception, where inhibition of ovulation is not
             the primary mode of action

          -  intrauterine device (IUD)

          -  intrauterine hormone-releasing system ( IUS)

          -  bilateral tubal occlusion

          -  vasectomised partner

          -  sexual abstinence

          -  male or female condom with or without spermicide

          -  cap, diaphragm or sponge with spermicide

        Exclusion Criteria:

        - Subjects are excluded from participation in the study if any of the following criteria
        apply:

          1. Known allergy to Nifedipine

          2. Unwilling to stop all other concomitant topical preparations applied in and around
             the anus from screening through the end of the study

          3. Subfissure injection of botulinum toxin in the 3 months prior to screening.

          4. Fissure resulting from inflammatory bowel disease, venereal disease, perianal
             psoriasis, immunodeficiency syndrome

          5. Atypical fissure (occurs off the midline) in which secondary causes were not
             excluded.

          6. Deemed by the investigator as anal fissure for which surgery is indicated

          7. Anal abscess;

          8. Grade 4 hemorrhoids

          9. Fixed anal stenosis

         10. Active or past history of cardiovascular or cerebrovascular disease including but not
             limited to angina pectoris, myocardial infarction, transient ischemic attacks/stroke,
             arrhythmia or ecg changes that requires medical treatment or deemed by the
             investigator as clinically significant, moderate to severe congestive heart failure,
             or cardiac valve abnormalities;

         11. Type 1 diabetes mellitus

         12. Insulin treated type 2 diabetes mellitus

         13. Renal failure defined as a serum creatinine &gt; 1.5 mg/dL (133 µmol/L) at screening

         14. Liver disease defined as Aspartate aminotransferase (AST) or alanine
             aminotransferase(ALT) &gt;2 X upper limit of normal at screening

         15. Malignant disease within 3 years of screening

         16. Has uncontrolled hypertension (sitting blood pressure &gt;160/95 mmHg at screening)

         17. History of chronic gastrointestinal disease such as Crohn's disease or ulcerative
             colitis

         18. History of major rectal surgery

         19. History of HIV, Hepatitis B, Hepatitis C

         20. Has clinical laboratory test values (chemistry, hematology, or urinalysis) judged to
             be clinically significant by the investigator at screening;

         21. Has used, in the last two weeks, drugs that may affect blood coagulation, such as
             Aspirin at a dose higher than 500 mg/day, Warfarin, Sintrom, Enoxaparin, Nadroparin,
             Heparin, Clopidogrel, Ticlopidine Rivaroxaban, Apixaban, Edoxaban

         22. Is treated with drugs that may affect the anal sphincter:

               -  Calcium channel blockers such as Nifedipine, Diltiazem or Verapamil

               -  Nitroglycerin or nitrates

         23. Has, upon physical examination, a rectal deformation or signs of rectal disease such
             as fistula, infection or space occupying lesion

         24. Participated in a clinical study in the last 30 days prior to screening.

         25. Is an immediate family member of personnel directly affiliated with the study at the
             investigative site, or is personally directly affiliated with the study at the
             investigative site; or is employed or related to the Sponsor, CRO or investigator;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nir Barak, MD</last_name>
    <phone>3023199970</phone>
    <email>barak@rddpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robert Shleypak</last_name>
    <phone>+972 54 663 70 80</phone>
    <email>robert@rddpharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UMHAT &quot;Sveti Georgi&quot;, Internal Consulting Department</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aleksandar Petrov</last_name>
      <phone>+359 88 8544732</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>II MHAT, Internal Clinic, Department of Gastroenterology</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikolay Tsonev, MD</last_name>
      <phone>+359 898 600972</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MC Health BG EOOD</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hristo Vrachev</last_name>
    </contact>
    <contact_backup>
      <email>office@healthcompanybg.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment Lulin</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Stoychev</last_name>
      <phone>+359 887 920 550</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MC &quot;New rehabilitation centre'' EOOD</name>
      <address>
        <city>Stara Zagora</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariana Penkova, MD</last_name>
      <email>mpenkovadoc@abv.bg</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IMSP Spitalul Clinic Municipal Nr 1</name>
      <address>
        <city>Chisinau</city>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eugen Gutu, Dr.</last_name>
      <phone>(373)22 276389</phone>
      <email>evghenii.gutu@usmf.md</email>
    </contact>
    <contact_backup>
      <last_name>Gugava Vahtang, Dr.</last_name>
      <phone>(373)60121911</phone>
      <email>vahtang@gugava.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>IMSP Spitalul Clinic Municipal Nr 3 &quot;Sfanta Treime&quot;</name>
      <address>
        <city>Chisinau</city>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gheorghe Anghelici, Prof.</last_name>
      <phone>(373)22492123</phone>
      <email>gh_anghelici@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Elvira Andon, Dr.</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>IMSP Spitalul Clinic Republican</name>
      <address>
        <city>Chisinau</city>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valentin Bendelic, Dr.</last_name>
      <phone>(373)79468229</phone>
      <email>vcbendelic@rambler.ru</email>
    </contact>
    <contact_backup>
      <last_name>Vadim Turcan, Dr.</last_name>
      <phone>(373)69212346</phone>
      <email>vadim.turcan@usmf.md</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Med-Gastr Centrum Medyczne</name>
      <address>
        <city>Lodz</city>
        <zip>91-034</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arkadiusz Mamos, Dr.</last_name>
      <phone>48502357277</phone>
      <email>arkadiusz.mamos@medgastr.pl</email>
    </contact>
    <contact_backup>
      <last_name>Milena Mamos</last_name>
      <phone>48533892015</phone>
      <email>milena.myssera@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Ambulatorium Medyczne Medical Hair &amp; Esthetic</name>
      <address>
        <city>Lublin</city>
        <zip>20-844</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piotr Niedziela, Dr.</last_name>
      <phone>48501235678</phone>
      <email>adwomed.niedziela@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Grażyna Wierzbowicz, RN</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centrum Innowacyjnych Terapii Sp. z o.o. Oddział w Piasecznie</name>
      <address>
        <city>Piaseczno</city>
        <zip>05-500</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Radosław Samsel, Dr.</last_name>
      <phone>48502233273</phone>
      <email>radoslaw.samsel@citrials.pl</email>
    </contact>
    <contact_backup>
      <last_name>Rafał Szurnicki, Dr.</last_name>
      <phone>48222905350</phone>
      <email>rafal.szurnicki@citrials.pl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>NZOZ Specjalistyczne Centrum Medyczne Flebo</name>
      <address>
        <city>Wolomin</city>
        <zip>05-200</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Przemysław Ciesielski, Dr.</last_name>
      <phone>48607575416</phone>
      <email>drprzemyslawciesielski@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Maria Ciesielska, Dr.</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Pelican Impex SRL</name>
      <address>
        <city>Oradea</city>
        <state>Jud. Bihor</state>
        <zip>410469</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Ioana Purza, Dr.</last_name>
      <phone>40259477074</phone>
      <email>andreapurge@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Adriana Boros</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>IRGH</name>
      <address>
        <city>Cluj Napoca</city>
        <state>Jud. Cluj</state>
        <zip>400162</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dan Dumitrascu, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tvm Med Serv Srl</name>
      <address>
        <city>Cluj Napoca</city>
        <state>Jud. Cluj</state>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alina Tantau, Dr.</last_name>
      <phone>40264598465</phone>
      <email>alitantau@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Irina Ioana Visovan, Dr.</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Institutul Regional de Gastroenterologie si Hepatologie &quot;Prof. Dr. Octavian Fodor&quot;</name>
      <address>
        <city>Cluj-Napoca</city>
        <state>Jud. Cluj</state>
        <zip>400162</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iancu Cornel, Dr.</last_name>
      <phone>(4026) 443-9696</phone>
      <phone_ext>134</phone_ext>
      <email>dr_cornel_iancu@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Adrian Bartos, Dr.</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>SC Schnelbach Medical Care SRL</name>
      <address>
        <city>Ploiesti</city>
        <state>Jud. Prahova</state>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Irinel Petru Totolici, Dr.</last_name>
      <phone>40723241444</phone>
      <email>itotolici@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Gabriel Doru Surdu, Dr.</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Spit. Clinic Judetean de Urgenta &quot;Sf. Apostol Andrei&quot; Constanta</name>
      <address>
        <city>Constanta</city>
        <state>Judet Constanta</state>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andra Iulia Suceveanu, Dr.</last_name>
      <phone>40755569029</phone>
      <email>andrasuceveanu@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Adrian Suceveanu</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Dacmed SRL</name>
      <address>
        <city>Ploiesti</city>
        <state>Judetul Prahova</state>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristian Ioan Dumitru, Dr.</last_name>
      <phone>40727765572</phone>
      <email>dumcristi58@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Gabriel Doru Surdu, Dr.</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centrul Medical de Diagnostic si Tratament Ambulator Neomed SRL</name>
      <address>
        <city>Brasov</city>
        <zip>500283</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrian Gabriel Moraru, Dr.</last_name>
      <email>interne@neomed.org</email>
    </contact>
    <contact_backup>
      <last_name>Stefan Sinbotean</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Institutul Clinic Fundeni</name>
      <address>
        <city>Bucharest</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Laura Iliescu, Dr.</last_name>
      <phone>40722235695</phone>
      <email>laura_ate@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Luminita Madalina Leurzeanu, Dr.</last_name>
      <phone>40726458402</phone>
      <email>luminitaleurzeanu@yahoo.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centrul Medical Sfanta Vineri SRL</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ion-Eugeniu Craciun, Dr.</last_name>
      <phone>40726725604</phone>
      <email>asistenta.sfvineri@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Adrian Ghenea, Dr.</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Moldova, Republic of</country>
    <country>Poland</country>
    <country>Romania</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 23, 2017</lastchanged_date>
  <firstreceived_date>August 10, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fissure in Ano</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nifedipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
